A higher dose of enzyme therapy in patients with classic infantile Pompe disease seems to improve ventilator-free survival and motor function

Documenti analoghi

• Antibody formation to enzyme therapy in classic infantile Pompe disease: implications of patient age
  di: van Gelder, C, et al.
  Pubblicazione: (2013)
• Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study
  di: van Gelder, C. M., et al.
  Pubblicazione: (2016)
• Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease
  di: van Gelder, Carin M., et al.
  Pubblicazione: (2014)
• Cognitive outcome of classic infantile Pompe patients receiving enzyme therapy
  di: Ebbink, BJ, et al.
  Pubblicazione: (2013)
• Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
  di: Kanters, Tim A, et al.
  Pubblicazione: (2014)